Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans

Psychopharmacology

Volumn 124, Issue 3, 1996, Pages 261-266

  Rockstroh, S ^a,c   Emre, M ^a   Tarral, A ^b   Pokorny, R ^a  

^a Sandoz Pharma Ltd   (Switzerland)

^b Laboratoires Sandoz   (France)

^c NONE   (Germany)

Author keywords

Attention; Excitatory amino acid antagonist; Memory; NMDA receptor

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEW DRUG; PLACEBO;

ADULT; AMNESIA; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SPATIAL MEMORY; TASK PERFORMANCE; VERBAL MEMORY;

ADULT; ATTENTION; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; MEMORY; PIPERAZINES;

EID: 0029872029     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246666     Document Type: Article

References (31)

1. Aebischer B, Frey P, Haerter H-P, Herrling PL, Mueller W, Olverman HJ, Watkins JC (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv Chim Acta 72: 1043-1047
2. Barnes CA (1990) Effects of aging on the dynamics of information processing and synaptic weight changes in the mammalian hippocampus. Prog Brain Res 86:89-104
3. Bäumler G (1974) Lern- und Gedächtnistest: LGT-3. Hogrefe, Göttingen
4. Bowen DM, Steele JE, Lowe SL, Palmer AM (1990) Tacrine in relation to amino acid transmitters in Alzheimer's disease. Adv Neurol 51:91-96
5. Bunney WE, Bunney BG (1990) A view of psychopharmacology, neuroscience, and the major psychoses. In: Bunney WE, Hippius H, Laakmann G, Schmauß M (eds) Neuropsychopharmacology. Springer, Berlin, Heidelberg, New York, pp 11-23
6. Carlsson A (1990) Perspectives on dopamine as a regulator of brain function. In: Bunney WE, Hippius H, Laakmann G, Schmauß M (eds) Neuropsychopharmacology. Springer, Berlin Heidelberg, New York, pp 2-10
7. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171-182
8. Difazio MC, Hollingsworth Z, Young AB, Penney JB (1992) Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology 42:402-406
9. Eccles JC (1990) Developing concepts of the synapses. J Neurosci 10:3769-3781
10. Foster AC (1990) Physiology and pathophysiology of excitatory amino acid neurotransmitter systems in relation to Alzheimer's disease. Adv Neurol 51:97-102
11. Ingram DK, Spangler EL, Iijima S, Ikari H, Kuo H, Greig NH, London ED (1994) Rodent models of Alzheimer dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Life Sci 55:2037-2049
12. Izquierdo I (1991) Role of NMDA receptors in memory. Trends Pharmacol Sci 12:128-129
13. Izquierdo I (1994) Pharmacological evidence for the role of long-term potentiation in memory. FASEB J 8:1139-1145
14. Izquierdo I, Medina JH (1993) Role of the amygdala, hippocampus and entorhinal cortex in memory consolidation and expression. Braz J Med Biol Res 26:573-589
15. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
16. Karobath M (1990) Pharmaceutical approaches to the treatment of dementia. In: Orgogozo JM, Gottfries CG (eds) Progress in dementia research. Parthenon Publishing, New Jersey, pp 99-109
17. Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Schizophrenia: a biochemical hypothesis. Nervenarzt 55:602-606
18. Kristensen MO, Gutmann NC, Christensen JE, Ostergaard K, Rasmussen K (1993) Serum cobalamin and methyl malonic acid in Alzheimer dementia. Acta Neurol Scand 87:475-481
19. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
20. Liang KC, Lin MH, Tyan YM (1993) Involvement of amygdala N-methyl-D-aspartate receptor in long-term retention of an inhibitory avoidance response in rats. Chin J Physiol 36:47-56
21. Malenka RC (1991) Postsynaptic events mediating LTP. In: Wheal H, Thompson A (eds) Excitatory amino acids and synaptic transmission. Academic Press, London, pp 303-314
22. Oye I, Paulson O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209-1213
23. Pitts LH, McIntosh TK (1990) Dynamic changes after brain trauma. In: Visken PJ, Bruyn GW, Klawans HL, Braakman R (eds) Head injury. Elsevier, Amsterdam, pp 70-93
24. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994) Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257:7-12
25. Rickard NS, Poot AC, Gibbs ME, Ng KT (1994) Both non-NMDA and NMDA glutamate receptors are necessary for memory consolidation in the day-old chick. Behav Neural Biol 62:33-40
26. Rose SP (1991) The biochemistry of memory. Essays Biochem 26:1-12
27. Scatton B (1993) The NMDA receptor complex. Fundam Clin Pharmacol 7:389-400
28. Scatton B, Carter C, Dana C, Benavides J (1991) NMDA receptor antagonists: treatment of brain ischemia. Drug News Persp 4:89-102
29. Siesjö BK, Memzawa H, Smith ML (1991) Neurocytotoxicity: pharmacological implications. Fundam Clin Pharmacol 5:755-767
30. Sohlberg MM, Mateer CA (1987) Effectiveness of an attention-training program. J Clin Exp Neuropsychiatr 9:117-130
31. Tamminga CA, Cascella N, Fakouhi TD, Herting RL (1992) Enhancement of NMDA-mediated transmission in schizophrenia: effects of milacemide. In: Meltzer HY (ed) Novel antipsychotic drugs. Proceedings of a symposium held in San Juan. Raven Press, New York, pp 171-177